AstraZeneca PLC (AZNCF)

Market Cap	202.20B
Revenue (ttm)	51.21B
Net Income (ttm)	6.50B
Shares Out	n/a
EPS (ttm)	4.15
PE Ratio	31.13
Forward PE	n/a
Dividend	1.00 (0.74%)
Ex-Dividend Date	Aug 8, 2024

Volume	3,400
Open	128.50
Previous Close	132.65
Day's Range	128.50 - 132.50
52-Week Range	118.16 - 175.00
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.